Roche's NXT007 Shows No Treated Bleeds In Highest Dose Groups, Advancing Toward Phase III Trials For Haemophilia A

+2.56%

-1.77%

-1.80%

ROCHE HOLDINGS AG

RHHBF

346.45

+2.56%

ROCHE HOLDINGS AG

RHHBY

40.49

-1.77%

ROCHE HOLDINGS AG

RHHVF

324.49

-1.80%

Positive phase I/II data presented at the 2025 International Society on Thrombosis and Haemostasis (ISTH) Congress show NXT007 achieved no bleeds requiring treatment in the highest dose groups in people with haemophilia A1
The NXT007 clinical development programme aims to normalise haemostasis and minimise treatment burden2,3
- Three phase III clinical studies on NXT007, a next-generation bispecific antibody, set to begin in 20261

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.